The PAX LC Trial: A Decentralized Study of Paxlovid in Adult Participants with Long COVID

If you believe you have Long COVID, you may be eligible to participate in a free and confidential study researching an investigational drug, Paxlovid, in patients with Long COVID. The study is for people who were in good or excellent health before getting COVID-19 and are now impaired. People will be randomized to 15 days of Paxlovid (nirmatrelvir/ritonavir) or placebo (placebo/ritonavir). The study will also be assessing each person’s immune system before and after receiving the study drug. Drs. Harlan Krumholz and Akiko Iwasaki are leading the study.

You can participate in this study completely remotely, and you would not need to travel to the Yale site.

Compensation up to $500.

To learn more or see if you are eligible to participate, please visit the PAX LC study website or email the study team at YalePaxStudy@yale.edu.